ADVI­TOS GmbH

ADVI­TOS GmbH devel­ops the CE-cer­ti­fied and world­wide pat­en­ted ADVOS ther­apy (ADVanced Organ Sup­port) — the first ther­apy for multi-organ sup­port integ­rated in a single device. The ADVOS pro­ced­ure improves patient sur­viv­al by sim­ul­tan­eously sup­port­ing the three main detox­i­fic­a­tion organs of the human body: liv­er, lungs and kid­neys. The ther­apy provides flu­id-based remov­al of water-sol­uble tox­ins (kid­ney), pro­tein-bound tox­ins (liv­er, kid­ney), and CO2 (lung). In addi­tion, ADVOS enables rap­id cor­rec­tion of acid-base bal­ance through tar­geted alter­a­tion of blood pH. ADVOS ther­apy is used in intens­ive care units at 20 lead­ing hos­pit­als through­out Ger­many and is on its way to per­meate the inter­na­tion­al mar­ket as well. ADVI­TOS GmbH receives fund­ing from the European Uni­on’s Hori­zon 2020 research and innov­a­tion program.